ArticleJournal of hematology & oncology2022

Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma.

Vivian Changying Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.